Sei Investments Co. Acquires 174,770 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN)

Sei Investments Co. increased its holdings in shares of Myriad Genetics, Inc. (NASDAQ:MYGN) by 7.4% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 2,526,761 shares of the company’s stock after purchasing an additional 174,770 shares during the period. Sei Investments Co. owned 2.78% of Myriad Genetics worth $34,642,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Quest Partners LLC boosted its position in Myriad Genetics by 50.8% during the 3rd quarter. Quest Partners LLC now owns 8,001 shares of the company’s stock valued at $219,000 after acquiring an additional 2,697 shares in the last quarter. Segall Bryant & Hamill LLC bought a new stake in Myriad Genetics during the third quarter valued at about $832,000. Connor Clark & Lunn Investment Management Ltd. grew its stake in Myriad Genetics by 426.1% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 115,036 shares of the company’s stock valued at $3,151,000 after purchasing an additional 93,171 shares during the last quarter. Intech Investment Management LLC raised its holdings in Myriad Genetics by 32.0% in the third quarter. Intech Investment Management LLC now owns 29,055 shares of the company’s stock worth $796,000 after purchasing an additional 7,043 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Myriad Genetics by 4.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,083,302 shares of the company’s stock valued at $29,672,000 after buying an additional 41,374 shares during the last quarter. 99.02% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

MYGN has been the topic of a number of analyst reports. Raymond James reaffirmed an “outperform” rating and issued a $19.00 price objective (down previously from $27.00) on shares of Myriad Genetics in a research report on Tuesday, February 25th. Leerink Partners downgraded Myriad Genetics from an “outperform” rating to a “market perform” rating and reduced their price target for the stock from $30.00 to $21.00 in a research report on Monday, December 9th. Craig Hallum initiated coverage on Myriad Genetics in a research report on Wednesday, February 12th. They issued a “buy” rating and a $29.00 price objective for the company. Bank of America reduced their target price on Myriad Genetics from $13.00 to $11.00 and set an “underperform” rating on the stock in a research report on Monday, March 3rd. Finally, UBS Group lowered their price target on Myriad Genetics from $18.00 to $16.00 and set a “neutral” rating for the company in a report on Tuesday, February 25th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $21.89.

Myriad Genetics Trading Down 0.3 %

Shares of Myriad Genetics stock opened at $9.98 on Tuesday. The stock has a market cap of $911.26 million, a PE ratio of -7.68 and a beta of 1.79. The firm has a fifty day moving average price of $12.05 and a 200 day moving average price of $16.92. Myriad Genetics, Inc. has a 1 year low of $9.36 and a 1 year high of $29.30. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.90 and a quick ratio of 1.73.

Myriad Genetics (NASDAQ:MYGN) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.12). The company had revenue of $210.60 million during the quarter, compared to analyst estimates of $210.35 million. Myriad Genetics had a negative net margin of 14.09% and a negative return on equity of 4.51%. During the same period last year, the firm earned ($0.12) EPS. Equities research analysts predict that Myriad Genetics, Inc. will post -0.3 earnings per share for the current year.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.